Dr Reddy’s Laboratories Announces Launch Of Bivalirudin For Injection In The U.S. Market

Dr Reddy’s Laboratories Limited, through a BSE filing on Tuesday announced that it has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax for Injection, approved by the US Food and Drug Administration (USFDA).

The Angiomax brand and generic had US sales of approx $198 million MAT for the most recent 12 months ending in March 2017 according to IMS Health. Angiomax is a registered trademark of the Medicines Company, it also said.

Dr Reddy’s Laboratories Limited was trading at Rs 2536.65, up by Rs 1.70, or 0.07 as at 11.30 on Tuesday, on the BSE. The stock had hit a high of Rs 2543.

For Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔

Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.